We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Acasti Pharma Inc (ACST) NPV A

Sell:2.14 CAD Buy:2.18 CAD Change: No change
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Sell:2.14 CAD
Buy:2.18 CAD
Change: No change
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Sell:2.14 CAD
Buy:2.18 CAD
Change: No change
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.

Contact details

Address:
102-3009 boul. de la Concorde E
LAVAL
H7E 2B5
Canada
Telephone:
+1 (450) 6864555
Website:
https://www.acastipharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACST
ISIN:
CA00430K8730
Market cap:
93.36 million CAD
Shares in issue:
44.29 million
Sector:
Pharmaceuticals
Exchange:
Canadian Venture Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Roderick Carter
    Independent Chairman of the Board
  • Janelle D'Alvise
    President, Chief Executive Officer, Director
  • Brian Ford
    Chief Financial Officer
  • Pierre Lemieux
    Chief Operating Officer, Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.